Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17837310 | 0.97 | SMN1; SMN2 (0.34) | SMN1; SMN2L3MBTL1ALDH1A1HCRTR2EPHX1 | |
| SCHEMBL17837305 | 0.95 | SMN1; SMN2 (0.33) | SMN1; SMN2L3MBTL1ALDH1A1HCRTR2EPHX1 | |
| SCHEMBL19576702 | 0.82 | CYP2C19 (0.37) | L3MBTL1ALDH1A1HCRTR2EPHX1DRD2 | |
| SCHEMBL17837249 | 0.80 | SMN1; SMN2 (0.30) | SMN1; SMN2 | |
| SCHEMBL17854720 | 0.79 | HCRTR2 (0.35) | SMN1; SMN2L3MBTL1ALDH1A1HCRTR2TDP1 | |
| SCHEMBL17854725 | 0.77 | GAA (0.34) | L3MBTL1HCRTR2EPHX1DRD2TDP1 | |
| SCHEMBL22487077 | 0.77 | GAA (0.34) | L3MBTL1HCRTR2EPHX1DRD2TDP1 | |
| SCHEMBL8980371 | 0.77 | CYP3A4 (0.33) | ALDH1A1GAA | |
| SCHEMBL17837296 | 0.77 | ALDH1A1 (0.38) | SMN1; SMN2ALDH1A1DRD2 | |
| SCHEMBL17837303 | 0.76 | FAAH (0.38) | SMN1; SMN2ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11377396-B2 | Enantioselective synthesis of α-quaternary Mannich adducts by palladium-catalyzed allylic alkylation | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-07-05 | — | — | US | disclosed |
| US-11377396-B2 | Enantioselective synthesis of α-quaternary Mannich adducts by palladium-catalyzed allylic alkylation | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-07-05 | — | — | US | disclosed |
| US-20200157020-A1 | ENANTIOSELECTIVE SYNTHESIS OF ALPHA-QUATERNARY MANNICH ADDUCTS BY PALLADIUM-CATALYZED ALLYLIC ALKYLATION | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2020-05-21 | — | — | US | disclosed |
| US-20200157020-A1 | ENANTIOSELECTIVE SYNTHESIS OF ALPHA-QUATERNARY MANNICH ADDUCTS BY PALLADIUM-CATALYZED ALLYLIC ALKYLATION | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2020-05-21 | — | — | US | disclosed |
| US-10421696-B2 | Enantioselective synthesis of α-quaternary mannich adducts by palladium-catalyzed allylic alkylation | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2019-09-24 | — | — | US | disclosed |
| US-10421696-B2 | Enantioselective synthesis of α-quaternary mannich adducts by palladium-catalyzed allylic alkylation | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2019-09-24 | — | — | US | disclosed |
| US-20160176773-A1 | ENANTIOSELECTIVE SYNTHESIS OF alpha-QUATERNARY MANNICH ADDUCTS BY PALLADIUM-CATALYZED ALLYLIC ALKYLATION | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2016-06-23 | — | — | US | disclosed |
| US-20160176773-A1 | ENANTIOSELECTIVE SYNTHESIS OF alpha-QUATERNARY MANNICH ADDUCTS BY PALLADIUM-CATALYZED ALLYLIC ALKYLATION | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2016-06-23 | — | — | US | disclosed |
| US-20160176773-A1 | ENANTIOSELECTIVE SYNTHESIS OF alpha-QUATERNARY MANNICH ADDUCTS BY PALLADIUM-CATALYZED ALLYLIC ALKYLATION | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11377396-B2 | Enantioselective synthesis of α-quaternary Mannich adducts by palladium-catalyzed allylic alkylation | ALG8, MANBA, MAN2A1 | SMN1; SMN2 3619/4885L3MBTL1 4303/4885ALDH1A1 122/4885 |
| US-10421696-B2 | Enantioselective synthesis of α-quaternary mannich adducts by palladium-catalyzed allylic alkylation | ALG8, MANBA, MAN2A1 | SMN1; SMN2 3619/4885L3MBTL1 4303/4885ALDH1A1 122/4885 |
| US-20160176773-A1 | ENANTIOSELECTIVE SYNTHESIS OF alpha-QUATERNARY MANNICH ADDUCTS BY PALLADIUM-CATALYZED ALLYLIC ALKYLATION | ALG8, MANBA, MAN2A1 | SMN1; SMN2 3564/4885L3MBTL1 4239/4885ALDH1A1 156/4885 |
| US-20200157020-A1 | ENANTIOSELECTIVE SYNTHESIS OF ALPHA-QUATERNARY MANNICH ADDUCTS BY PALLADIUM-CATALYZED ALLYLIC ALKYLATION | ALG8, MANBA, MAN2A1 | SMN1; SMN2 3564/4885L3MBTL1 4239/4885ALDH1A1 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.